WO2022154463A1 - Particules composites organométalliques et composition comprenant ces particules composites organométalliques - Google Patents

Particules composites organométalliques et composition comprenant ces particules composites organométalliques Download PDF

Info

Publication number
WO2022154463A1
WO2022154463A1 PCT/KR2022/000539 KR2022000539W WO2022154463A1 WO 2022154463 A1 WO2022154463 A1 WO 2022154463A1 KR 2022000539 W KR2022000539 W KR 2022000539W WO 2022154463 A1 WO2022154463 A1 WO 2022154463A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
metal
composite particles
organic
benzene
Prior art date
Application number
PCT/KR2022/000539
Other languages
English (en)
Korean (ko)
Inventor
최경민
이현신
강서영
Original Assignee
랩인큐브 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210192388A external-priority patent/KR20220103624A/ko
Application filed by 랩인큐브 주식회사 filed Critical 랩인큐브 주식회사
Publication of WO2022154463A1 publication Critical patent/WO2022154463A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Definitions

  • the present invention relates to a metal-organic composite particle formed by combining a metal and an organic material.
  • Nanomaterials that combine molecules to form pores have emerged as a major research field for the past few decades, and are being applied in various fields such as catalysts, adsorption/separation/storage, electronics, health care, semiconductors, food, and detergents.
  • Nanomaterials having these pores have very high adsorption performance, can control adsorption performance, can create active sites in the backbone, have pore sizes similar to biomolecules, and have excellent ion exchange with most pores ability, and also has insulator, semiconductor and conductor properties.
  • the metal-organic framework is a porous material in which a metal ion cluster and an organic linker or organic bridging ligands are linked by a coordination bond to form a three-dimensional structure. Since the metal-organic framework has an open pore structure as well as a large surface area, it is possible to move a large amount of molecules or solvents compared to other known porous materials.
  • One object of the present invention is to provide a metal-organic composite particle that can be used to adsorb, store and release a substance having the same size as a molecular gas to a substance having a size larger than that of a molecular gas, such as drugs, proteins, DNA, RNA, and cells. .
  • Another object of the present invention is to provide a composition that can be used to slowly release the active material by adhering to or mixing with a variety of objects and having a higher amount of active material than the metal-organic framework.
  • Another object of the present invention is to provide a composition that can be used for alleviating or removing inflammation by efficiently adsorbing substances such as protein signaling substances that cause inflammation.
  • a first aspect of the present invention for achieving the above object is a composite particle formed by combining a metal and an organic material, wherein a peak indicating crystallinity is not observed in the powder X-ray diffraction analysis of the composite particle, and the TEM electron In the diffraction analysis, it has a structure in which a ring-shaped diffraction pattern is observed, a plurality of pores having a size of 1 nm to 10 ⁇ m are formed inside the composite particle, and it is to provide a metal-organic composite particle including a supported active ingredient. .
  • a second aspect of the present invention for achieving the other object includes a biodegradable polymer, a composite particle formed by combining a metal and an organic material dispersed in the biodegradable polymer, and an active ingredient supported on the composite particle, ,
  • the composite particle has a structure in which a peak indicating crystallinity is not observed in powder X-ray diffraction analysis, and a ring-shaped diffraction pattern is observed in TEM electron diffraction analysis, and the inside of the composite particle has a size of 1 nm to 10 ⁇ m It is to provide a composition in which a plurality of pores are formed, and at least a portion of the active ingredient is supported in the plurality of pores.
  • the metal-organic composite particles according to the present invention can be used to adsorb, store, or release materials of a relatively large size, such as drugs, proteins, DNA, RNA, and cells, from small-sized substances such as molecular gases together, so that the metal-organic framework It can be used for adsorption, storage and release of a variety of substances compared to
  • composition according to an embodiment of the present invention exhibits significantly improved active material loading and dispersibility compared to the sustained-release composition using the metal-organic framework powder, and when used in medical or cosmetic fields, treatment, prevention, and cosmetic properties can be improved.
  • composition according to an embodiment of the present invention can be used for alleviating or removing inflammation by efficiently adsorbing and removing substances such as protein signaling substances that cause inflammation.
  • Example 1 is a scanning electron microscope image of the composite particles prepared according to Example 1 of the present invention.
  • Example 4 is a transmission electron microscope image of the composite particles prepared according to Example 1 of the present invention.
  • Example 6 shows the results of powder X-ray diffraction analysis of the composite particles prepared according to Example 1.
  • 16 is a photograph comparing the sustained-release coatings of Examples 2 and 3 coated on a plastic spoon with those coated with PLGA.
  • the metal-organic composite particle according to the present invention is a composite particle formed by combining a metal and an organic material, and in the composite particle, a peak indicating crystallinity is not observed in powder X-ray diffraction analysis, and a ring shape in TEM electron diffraction analysis It has a structure in which the diffraction pattern of the composite particle is observed, and a plurality of pores having a size of 1 nm to 10 ⁇ m are formed inside the composite particle, and it is characterized in that it contains a supported active ingredient.
  • the metal-organic composite particles according to the present invention unlike the metal-organic framework, a peak enough to confirm crystallinity was not observed in powder X-ray diffraction analysis, whereas a ring-shaped diffraction pattern was observed in TEM electron diffraction analysis. It is observed. That is, it has crystallinity of a fine short range order on an amorphous basis.
  • a plurality of pores having a size of 1 nm to 10 ⁇ m, which are not formed in the metal-organic framework have a microstructure formed therein.
  • 'a plurality of pores formed in the interior of the composite particle' is an open type of pores that are depressed from the surface of the composite particle toward the inside, and a closed shape inside the composite particle. It is used in the meaning of including all qigong.
  • the shape of the adsorption/desorption curve may indicate adsorption by a plurality of multi-composite pores increasing at all pressures.
  • 'adsorption by a plurality of multi-composite pores' means adsorption in a form in which adsorption by micropores, mesopores, and macropores all appear.
  • the metal-organic composite particle when a low-temperature gas adsorption analysis is performed, the adsorption/desorption curve shows that a large amount of gas is adsorbed at the beginning of the analysis, and then the amount of gas adsorption is slightly increased even if the partial pressure is increased. represents the pattern of In contrast, in the present invention, the metal-organic composite particle exhibits a multi-pore shape showing a rapid increase after a small amount of gas adsorption occurs in the initial stage of low-temperature gas adsorption analysis, and then linearly increases when the partial pressure increases.
  • the plurality of pores may adsorb one or more selected from molecular gas, drug, protein, DNA, virus, cell, intracellular signal transduction material (eg, protein signal material). it could be
  • the active ingredient may be, for example, at least one selected from the group consisting of organic acids, drugs, metal ions, oxides, molecular gases, tissue regeneration materials, and the like.
  • the metal is, for example, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd , Cd, La, W, Os, Ir, Pt, Au, Hg, Sm, Eu, Gd, Tb, Dy, Ho, Al, Ga, In, Ge, Sn, Pb, Li, Na, K, Rb, Cs , Mg, Ca, Sr, and may be at least one element selected from the group consisting of Ba, or an ion thereof.
  • the organic material is, for example, 4,4'-biphenyldicarboxilic acid, benzene-1,4-dicarboxylic acid (benzene- 1,4-dicarboxylic acid), 9,10-anthracenedicarboxylic acid, biphenyl-3,3,5,5'-tetracarboxylic acid (biphenyl-3,3,5) ,5'-tetracarboxylic acid, biphenyl-3,4',5-tricarboxylic acid, 5-bromoisophthalic acid, 5 -Cyano-1,3-benzenedicarboxylic acid (5-cyano-1,3-benzenedicarboxylic acid), 2,2-diamino-4,4'-stilbenedicarboxylic acid (2,2-diamino -4,4'-stilbenedicarboxylic acid), 2,5-diaminoterephthalic acid (2,5-diaminoterephthalic acid), 1,1,2,2-te
  • the metal-organic composite particles have a particle size of less than 0.01 ⁇ m or more than 100 ⁇ m, the amount of adsorption of the active material may not be sufficient, and thus, it is preferable to have a particle size of 0.01 to 100 ⁇ m.
  • the adsorption, storage and release properties of various substances of the metal-organic composite particles according to the present invention can be used for various purposes.
  • cosmetics substances for storing proteins, substances for storing antibacterial agents, additives for food and animal feed, substances for collecting harmful gases such as odor components, fine dust, radiation gas, substances for air purification, substances for collecting moisture, hydrogen or electronic parts
  • Gas storage materials such as process gases, materials for electrode materials for secondary batteries, materials for capacitors, materials for electrolytes in batteries, materials for gas sensors, materials for ion exchangers, pharmaceutical carriers for medical devices, coatings for contact lenses, sustained release animals It can be applied to drugs, sustained-release human drugs, sustained-release preventive drugs, food preservation containers, and deodorants.
  • the composition according to the present invention comprises a biodegradable polymer, a composite particle formed by combining a metal and an organic material dispersed in the biodegradable polymer, and an active ingredient supported on the composite particle, wherein the composite particle is a powder In X-ray diffraction analysis, a peak indicating crystallinity is not observed, and in TEM electron diffraction analysis, a ring-shaped diffraction pattern is observed, and a plurality of pores with a size of 1 nm to 10 ⁇ m are formed inside the composite particle. and at least a portion of the active ingredient may be supported in the plurality of pores.
  • the composition Since the composite particles carrying the active ingredient are dispersed in the biodegradable polymer, the composition has a sustained-release property such that the active ingredient supported on the composite particles is gradually released as the biodegradable polymer is decomposed.
  • the shape of the adsorption/desorption curve may represent the shape of the composite pores increasing at all pressures.
  • the metal is, for example, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh , Pd, Cd, La, W, Os, Ir, Pt, Au, Hg, Sm, Eu, Gd, Tb, Dy, Ho, Al, Ga, In, Ge, Sn, Pb, Li, Na, K, Rb , Cs, Mg, Ca, Sr, and may be at least one element selected from the group consisting of Ba, or an ion thereof.
  • the organic material is, for example, 4,4'-biphenyldicarboxylic acid (4,4'-biphenyldicarboxilic acid), benzene-1,4-dicar benzene-1,4-dicarboxylic acid, 9,10-anthracenedicarboxylic acid, biphenyl-3,3,5,5'-tetracarboxylic acid (biphenyl) -3,3,5,5'-tetracarboxylic acid), biphenyl-3,4',5-tricarboxylic acid (biphenyl-3,4',5-tricarboxylic acid), 5-bromoisophthalic acid (5 -bromoisophthalic acid), 5-cyano-1,3-benzenedicarboxylic acid (5-cyano-1,3-benzenedicarboxylic acid), 2,2-diamino-4,4'-stilbenedicarboxylic acid (2,2-diamino-4,4'-stilbenedicarboxylic acid (2,2-
  • the organic material may preferably include ⁇ -cyclodextrin, ⁇ -cyclodextrin, and ⁇ -cyclodextrin.
  • the organic material may include crosslinking of other organic molecules in addition to the above three types of cyclodextrins, thereby forming a gap between metals (ions) to form empty regions, that is, pores in the structure, and the size can be adjusted.
  • cyclodextrins when ⁇ -cyclodextrin is used, the space formed is the largest, and thus the ability to capture the active material is the best, so it may be the most preferred example.
  • the biodegradable polymer is, for example, polylactide-glycolide copolymer (PLGA), chitosan (chitosan), polydioxanone (polydioxanone), polylactide- polycaprolactone copolymer (PLA) -PCL), polyglycolide-polycaprolactone copolymer (PGA-PCL), polydioxanone-polycaprolactone copolymer (PDO-PCL), polytrimethylene carbonate (PTMC), polycarbonate (PC), poly Butylene succinate (PBS), polyhydroxybutyrate (PHB), polyhydroalkanoate (PHA), aliphatic polyphosphate ester, aromatic polyester (aromatic polyester) and polyphosphazene (Polyphosphazene) It may be one or more selected from the group consisting of.
  • PLGA polylactide-glycolide copolymer
  • chitosan chitosan
  • a copolymer is a polymer made by polymerizing two or more different monomers, and each monomer can be independently arranged, alternately arranged in a form, a certain part agglomerated, arbitrarily arranged in a form, one main chain It may be in a form linked to a side chain or in a form crosslinked by a side chain between the main polymer chains.
  • the copolymer may be an alternating copolymer, a random copolymer, a block copolymer, or a graft copolymer, but is not limited thereto.
  • the biodegradable copolymer may be a polylactide-glycolide copolymer (PLGA), and the polylactide-glycolide copolymer may have a molar ratio of lactide and glycolide of 0.1:1 to 9:1.
  • the polylactide-glycolide copolymer is coated on the metal-organic framework, so that the release pattern of the active material can be changed, and the release amount and release rate can be controlled according to the composition of the copolymer.
  • the biodegradable polymer may be 150 to 300 parts by weight based on 100 parts by weight of the metal-organic composite particles. More specifically, the weight ratio of the polylactide-glycolide copolymer may be 150 to 300 parts by weight based on 100 parts by weight of the metal-organic framework on which the active material is supported.
  • the weight ratio corresponds to the metal-organic framework may be coated with a biodegradable polymer, and if the weight of the biodegradable polymer is lower than 150, the release amount of the active ingredient may be small due to the uneven surface due to not being sufficiently coated, When the weight part of the biodegradable polymer is greater than 300, the thickness of the polymer coating of the metal-organic framework may be increased, and thus the amount of active ingredient released may be reduced.
  • the active ingredient may be, for example, at least one selected from the group consisting of organic acids, drugs, metal ions, oxides, molecular gases, tissue regeneration materials, and the like.
  • the tissue regeneration material may be at least one selected from the group consisting of protein, DNA, RNA, and stem cells.
  • the metal-organic composite particles may have an adsorption amount of the active material of 100 mg/g or more, preferably 150 mg/g or more, more preferably 250 mg/g or more, and most preferably 500 mg/g or more.
  • the adsorption amount of the active material may not be sufficient, so it is preferably made of 0.01 to 100 ⁇ m.
  • a solvent for dissolving the biodegradable polymer may be further included. That is, the composition may be used in a state in which the solvent for dissolving the biodegradable polymer is completely removed, or in a state in which the solvent is partially removed or not removed.
  • the solvent may be one selected from the group consisting of acetonitrile, chloroform, dichloromethane, water, ethyl acetate, acetone, ethanol and methanol, or a mixture thereof.
  • composition according to the present invention can be used for various purposes.
  • the composition may include an implant, stent, artificial bone, artificial joint, catheter or canola, hemostatic clip, vascular access device, peripheral blood vessel, intravenous site, drainage, gastrotrophic tube, airway tube, guide wire , pacemaker, organ regeneration guide tube, dental filler, dental support building resin, dental coating material, indwelling tube, suture, lifting thread, needle, sanitary napkin, tissue adhesion prevention material, contact lens, bone cement, dental use It can be used for sustained release of antibacterial/anti-inflammatory agents of articles that are inserted, attached, or applied to the human body, such as adhesives and medical casts.
  • the antibacterial/anti-inflammatory agent is not particularly limited as long as it can be supported on the metal-organic composite particles according to the present invention, but may be appropriately selected and used in consideration of the drug properties required for the object to be coated.
  • minocycline hydrochloride as an antibacterial/anti-inflammatory agent for dental implants (fixtures, abutments, crowns, etc.), dental fillers, resins for building dental supports, or ointments applied after mechanical cleaning of teeth (Minocycline Hydrochloride) and Tetracycline.
  • the antibacterial/anti-inflammatory agent When the antibacterial/anti-inflammatory agent is supported on the metal-organic composite particle according to the present invention and used in the form of a sustained-release coating, filler or ointment, due to the increase in the drug loading and the sustained-release effect, for example, antibacterial/anti-inflammatory after implantation.
  • the number of treatments ie, number of dental visits) can be significantly reduced.
  • trehalose, rapamycin, perhexiline, amiodarone, niclosamide which are substances that can be used for promoting autophagy after surgery on implants , rottlerin, torin1, PI103, phenylethylisothiocyanate, dexamethasone, lithium, L-690,330, carbamazepine, sodium valpro Sodium valproate, verapamil, loperamide, nimodipine, nitrendipine, niguldipine, nicardipine, pimozide, Calpastatin, calpeptin, clonidine, rilmenidine, 2',5'-dideoxyadenosine, NF449, minoxidil, penitrem A, spermidine, resveratrol, fluspirilene, trifluoperazine, small-molecule enhancer (SMER) 10, SMER 18, SMER 28 and A substance selected from
  • Metal-organic composite particles were prepared by the following process.
  • Cyclodextrin (Cyclodextrin) solution is prepared by putting 0.125 mmol (0.162 g) of cyclodextrin, 1 mmol (0.056 g) of KOH, 2 mL of deionized water (DI) and 2 mL of ethanol (EtOH) in a 10 mL glass bottle. Then, the prepared solution was rapidly dried with hot air at 120° C. to prepare a powder.
  • an active ingredient-supported sustained-release composition was prepared by the following process.
  • Ethanol 1 mL, CTAB (cetyltrimethylammonium bromide) 0.022mmol (0.008g), and tetracycline hydrochloride 0.21mmol (0.093g) were put into a 20mL glass bottle, and then supported on the powder prepared according to Example 1. .
  • a biodegradable polymer After dissolving PLGA, a biodegradable polymer, in 1 mL of acetone, it was added to the composite particles subjected to drug loading treatment, and stirred to prepare a coating agent in which the composite particles were homogeneously dispersed.
  • the coating agent thus prepared contained 0.15 g of PLGA, 1 mL of acetone, and 0.06 g of metal-organic composite particles, and the content of metal-organic composite particles was 6 wt%.
  • the theoretical content of this coating is 87.4 mg tetracycline /g total .
  • an active ingredient-supported sustained-release composition was prepared by the following process.
  • the sustained-release composition was prepared in the same manner as in Example 2, except that the coating agent contained 0.15 g of PLGA, 1 mL of acetone, and 0.15 g of metal-organic composite particles, and the content of metal-organic composite particles was 14 wt%. The theoretical content of this coating is 145.7 mg tetracycline /g total .
  • Metal-organic composite particles were prepared by the following process.
  • a 10mL glass bottle prepared with the cyclodextrin solution was placed in a 120mL container containing 20mL MeOH, and reacted for 6 hours in an oven maintained at 50°C without a lid to prepare a powder.
  • Ethanol 1 mL, CTAB (cetyltrimethylammonium bromide) 0.022 mmol (0.008 g), and tetracycline hydrochloride 0.21 mmol (0.093 g) were added to a 20 mL glass bottle, and then loaded onto the powder prepared according to Comparative Example 1. .
  • a biodegradable polymer After dissolving PLGA, a biodegradable polymer, in 1 mL of acetone, it was added to the composite particles subjected to drug loading treatment, and stirred to prepare a coating agent in which the composite particles were homogeneously dispersed.
  • the coating agent thus prepared contained 0.15 g of PLGA, 1 mL of acetone, and 0.06 g of metal-organic composite particles, and the content of metal-organic composite particles was 6 wt%.
  • the theoretical content of this coating is 87.4 mg tetracycline /g total .
  • an active ingredient-supported sustained-release composition was prepared by the following process.
  • the sustained-release composition was prepared in the same manner as in Comparative Example 2, except that the coating agent contained 0.15 g of PLGA, 1 mL of acetone, and 0.1 g of organic metal composite particles, and the content of the organic metal composite particles was 10% by weight.
  • the theoretical content of this coating is 15 mg tetracycline /g total .
  • Metal-organic composite particles were prepared by the following process.
  • FIG. 1 is a scanning electron microscope image of a composite particle prepared according to Example 1 of the present invention
  • FIG. 2 is a scanning electron microscope image of a metal-organic composite particle prepared according to Comparative Example 1
  • FIG. It is a scanning electron microscope image of metal-organic composite particles prepared according to
  • the metal-organic composite particles prepared according to Example 1 of the present invention are generally spherical particles, particles with one or both sides depressed, donut-shaped particles with a hole in the center, etc. It is mixed, and the surface of each particle has a rough surface.
  • the metal-organic composite particles prepared according to Comparative Example 1 are composed of cube-shaped particles with a smooth surface, as shown in FIG. 2 , and this shape is a typical shape of the metal-organic framework.
  • the metal-organic composite particles prepared according to Comparative Example 4 had irregular particle shapes and, unlike Comparative Example 1, did not form a smooth surface, and had a shape in which a large number of particles were agglomerated.
  • FIG. 4 is a transmission electron microscope image of the composite particles prepared according to Example 1 of the present invention
  • FIG. 5 is a transmission electron microscope image of the metal-organic composite particles prepared according to Comparative Example 1.
  • FIG. 6 shows the powder X-ray diffraction analysis results of the composite particles prepared according to Example 1
  • FIG. 7 shows the powder X-ray diffraction analysis results of the composite particles prepared according to Comparative Example 1
  • FIG. 8 shows the results of powder X-ray diffraction analysis of the composite particles prepared according to Comparative Example 4.
  • FIG. 9 shows the TEM electron diffraction analysis results of the composite particles prepared according to Example 1
  • FIG. 10 shows the TEM electron diffraction analysis results of the composite particles prepared according to Comparative Example 1
  • FIG. 11 is Comparative Example 4 TEM electron diffraction analysis results of the composite particles prepared according to the method are shown.
  • the composite particles prepared according to Example 1 showed a ring-type electron diffraction pattern diffracted by fine crystals in the electron diffraction analysis result of a transmission electron microscope. That is, in the composite particles prepared according to Example 1 of the present invention, crystallinity could not be confirmed within the resolution range of the powder X-ray diffraction apparatus, but the crystallinity of the short range order level was not confirmed in TEM. appears to have an organization.
  • the composite particles according to the present invention can be obtained from molecular gas, protein DNA, RNA, It is presumed to have the property of simultaneously adsorbing relatively large-sized substances such as cells.
  • FIG. 12 shows the low-temperature nitrogen adsorption analysis result of the powder of the composite particle prepared according to Example 1
  • FIG. 13 shows the low-temperature nitrogen adsorption analysis result of the powder of the composite particle prepared according to Comparative Example 1.
  • the adsorption/desorption curve shows a tendency to slightly adsorb at the initial stage when the partial pressure of the gas is low, and to increase the adsorption amount as the partial pressure increases.
  • the curve pattern shows a multi-composite pore shape in which microporous, mesoporous, and macroporous are mixed during low-temperature nitrogen adsorption analysis.
  • the adsorption/desorption curve shows a "microporous" in which the gas adsorption amount slightly increases even if the partial pressure increases after most of the gas is adsorbed in a state where the partial pressure of the gas is low. " represents the shape.
  • Example 14 shows the activity of the composite particles prepared in Example 1 (indicated as “metal-organic composite particles” in the drawing) and the composite particles prepared by Comparative Example 1 (indicated by "metal-organic frameworks” in the drawings); This is the result of comparing the absorption amount of the active substance according to the substance concentration.
  • the drug absorption amount of the metal-organic composite particles prepared according to Example 1 was increased by 9 to 18 times compared to the metal-organic framework prepared according to Comparative Example 1.
  • the absorption amount of the active material increased as the concentration of the active material increased, but in the case of the metal-organic framework prepared according to Comparative Example 1, the concentration of the active material increased. However, the absorption amount of the active material did not increase any more.
  • sustained-release coatings according to Examples 2 and 3 increased the drug release amount by about 17 to 22 times compared to Comparative Examples 2 and 3, and sustained release of the drug for 14 days or more is possible is also confirmed.
  • the sustained-release compositions prepared according to Examples 2 and 3 of the present invention carry a drug at least 17 times more than the sustained-release compositions of Comparative Examples 2 and 3, and can be released over a longer period of time. It has sustained release properties.
  • 16 is a photograph comparing the sustained-release coatings of Examples 2 and 3 coated on a plastic spoon with those coated with PLGA.
  • Example 1 dispersed in the sustained-release coating agents of Examples 2 and 3 have very good dispersibility on the surface of PLGA. This means that when the coating agent according to Examples 2 and 3 is coated on the target article, homogeneous medicinal effect can be expected in all coating layers.
  • a coating layer is formed in a state in which a plurality of particles are aggregated.
  • the particles are distributed and coated in such a form, there is a problem that an even drug effect cannot be expected throughout the coating layer.
  • the coating agents according to Examples 2 and 3 have significantly improved properties compared to the particles made of the metal-organic framework in terms of dispersibility of the drug-carrying particles.

Abstract

La présente invention concerne des particules composites qui sont formées par combinaison d'un ion métallique et d'un lieur organique ou d'un ligand organique et ont une structure poreuse capable de supporter un matériau fonctionnel. Les particules composites selon la présente invention sont des particules composites formées par combinaison d'un métal et d'un matériau organique, les particules composites ayant une structure dont l'analyse par diffraction des rayons X sur poudre ne présente pas de pic indiquant la cristallinité et dont l'analyse par diffraction d'électrons TEM présente un diagramme de diffraction en forme d'anneau, contenant une pluralité de pores dont la taille est de 1 nm à 10 μm, et comprenant des principes actifs supportés.
PCT/KR2022/000539 2021-01-15 2022-01-12 Particules composites organométalliques et composition comprenant ces particules composites organométalliques WO2022154463A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2021-0005844 2021-01-15
KR20210005844 2021-01-15
KR10-2021-0192388 2021-12-30
KR1020210192388A KR20220103624A (ko) 2021-01-15 2021-12-30 금속유기 복합입자 및 금속유기 복합입자를 포함하는 조성물

Publications (1)

Publication Number Publication Date
WO2022154463A1 true WO2022154463A1 (fr) 2022-07-21

Family

ID=82447329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/000539 WO2022154463A1 (fr) 2021-01-15 2022-01-12 Particules composites organométalliques et composition comprenant ces particules composites organométalliques

Country Status (1)

Country Link
WO (1) WO2022154463A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024019401A1 (fr) * 2022-07-20 2024-01-25 숙명여자대학교산학협력단 Particules composites organométalliques capables d'adsorber, de stocker ou de libérer au moins deux types de substances fonctionnelles et composition les comprenant

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100374098B1 (ko) * 1994-04-08 2003-06-09 아트릭스 라보라토리스, 인코포레이션 조절된방출이식편형성에적합한액체전달조성물
JP2006131577A (ja) * 2004-11-09 2006-05-25 Ltt Bio-Pharma Co Ltd 異なる粒子径を有する薬物封入ナノ粒子の作製方法および当該方法で得られたナノ粒子
KR20140098739A (ko) * 2011-09-21 2014-08-08 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. Ｓｉｒｎａ에 대한 나노 전달 시스템
KR101513318B1 (ko) * 2007-05-14 2015-04-17 가부시키가이샤 엘티티 바이오파마 서방성의 음하전기를 갖는 저분자 약물 함유 나노 입자
KR20170005977A (ko) * 2015-07-07 2017-01-17 한국과학기술원 기공이 형성된 미세 캡슐의 제조 방법 및 이에 의한 반투과성 미세캡슐

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100374098B1 (ko) * 1994-04-08 2003-06-09 아트릭스 라보라토리스, 인코포레이션 조절된방출이식편형성에적합한액체전달조성물
JP2006131577A (ja) * 2004-11-09 2006-05-25 Ltt Bio-Pharma Co Ltd 異なる粒子径を有する薬物封入ナノ粒子の作製方法および当該方法で得られたナノ粒子
KR101513318B1 (ko) * 2007-05-14 2015-04-17 가부시키가이샤 엘티티 바이오파마 서방성의 음하전기를 갖는 저분자 약물 함유 나노 입자
KR20140098739A (ko) * 2011-09-21 2014-08-08 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. Ｓｉｒｎａ에 대한 나노 전달 시스템
KR20170005977A (ko) * 2015-07-07 2017-01-17 한국과학기술원 기공이 형성된 미세 캡슐의 제조 방법 및 이에 의한 반투과성 미세캡슐

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024019401A1 (fr) * 2022-07-20 2024-01-25 숙명여자대학교산학협력단 Particules composites organométalliques capables d'adsorber, de stocker ou de libérer au moins deux types de substances fonctionnelles et composition les comprenant

Similar Documents

Publication Publication Date Title
US8034363B2 (en) Sustained release systems of ascorbic acid phosphate
EP2207577B1 (fr) Structure de polymère biodégradable et procédé pour la préparer
JP3131195B2 (ja) ヒドロゲル形成性で自己溶解性の吸収性ポリエステル共重合体およびその使用方法
KR100422391B1 (ko) 용융공정에의해펩티드를포함하는생분해가능한미소구의제조
KR101756493B1 (ko) 생분해성 하이드로겔의 살균
US6576263B2 (en) Delivery systems using preformed biodegradable polymer compositions and methods
EP0737703B1 (fr) Copolymères de polyesters, formateurs d'hydrogels, auto-solvatisants et absorbables ainsi que leurs procédés d'utilisation
FI80284B (fi) Farmaceutiskt eller veterinaert godtagbar amfipatisk blocksampolymer och dess framstaellning.
WO2022154463A1 (fr) Particules composites organométalliques et composition comprenant ces particules composites organométalliques
DK1968638T3 (en) Controlled release gels
WO2011081253A1 (fr) Système injectable d'agent de charge à microparticules poreuses
MXPA02006272A (es) Composicion liquida de copolimero de bloque biodegradable para sistema de suministro de farmaco y proceso para la prepa paracion del mismo.
WO2021154038A1 (fr) Structure métal-organique type à libération prolongée utilisant de la cyclodextrine et son procédé de fabrication
JP2005047928A (ja) 吸収可能なマイクロ粒子
TWI584825B (zh) 薄片成形體及止血材
AU2296699A (en) Process for making absorbable microparticles
CS417791A3 (en) Capsules or tablets with a controlled release
CA2778813A1 (fr) Copolymeres absorbables de diglycolate de polyethylene destines a reduire l'adhesion microbienne sur des implants et des dispositifs medicaux
Huang et al. Formation of antibiotic, biodegradable/bioabsorbable polymers by processing with neomycin sulfate and its inclusion compound with β‐cyclodextrin
KR20220103624A (ko) 금속유기 복합입자 및 금속유기 복합입자를 포함하는 조성물
WO2024019401A1 (fr) Particules composites organométalliques capables d'adsorber, de stocker ou de libérer au moins deux types de substances fonctionnelles et composition les comprenant
WO2019147065A1 (fr) Structures métallo-organiques photodégradables et procédé de préparation associé
CN104107165B (zh) 一种艾塞那肽微球制剂、其制备方法及其应用
WO2021045556A1 (fr) Implant biomédical comprenant des nanoparticules inorganiques modifiées en surface et un polymère biodégradable, et procédé de préparation associé
Jayasuriya et al. Optimization of scaled-up chitosan microparticles for bone regeneration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22739658

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22739658

Country of ref document: EP

Kind code of ref document: A1